Nektar Therapeutics (NKTR) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $75.50 +0.85%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
WPRT, ITRG, ALM, More
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
WPRT, ITRG, ALM, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.40), in-line with the analyst estimate of ($0.40). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $21.49 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
- Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c
- Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
